Bavarian Nordic gets US and EU approval for Denmark fill finish facility - BioPharma-Reporter.com

Bavarian Nordic A/S has received approvals from the US and EU regulatory authorities to manufacture its Jynneos/Imvanex smallpox and monkeypox vaccine at its fill and finish facility in Denmark.

With the approvals of the final drug production, the company is now allowed to deliver drug product manufactured at its own site to the US and EU market, instead of using a third party, allowing it t… [+1368 chars]

full article...